ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,355Medicare Part D Prescriptions Filled, Including Refills

Rank: 82 out of 1269

$635K Total Retail Price of All Prescriptions

Rank: 75 out of 1269

493 Patients Receiving at Least One Drug in Part D
86%Patients 65 Years and Older
29% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

5% of this provider’s 493 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

10% of this provider’s 493 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 8,324 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

24% of this provider’s prescriptions were for brand-name drugs, compared to an average of 26%.

Prescription Price

$68 was the average price of a prescription from this provider, compared to $69 among peers.

Prescriptions per Patient

19 is the average number of prescriptions (including refills) per patient, compared to an average of 18.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
LEVOTHYROXINE SODIUM 593 538 1 4
SIMVASTATIN 367 336 2 3
AMLODIPINE BESYLATE 347 323 3 2
LISINOPRIL 344 312 4 1
METOPROLOL TARTRATE 330 309 5 6
OMEPRAZOLE 272 250 6 8
METOPROLOL SUCCINATE 198 178 7 13
PRAVASTATIN SODIUM 194 168 8 11
CITALOPRAM HBR 192 157 9 21
ATORVASTATIN CALCIUM 178 151 10 7
HYDROCODONE-ACETAMINOPHEN 171 148 S3 11 20
HYDROCHLOROTHIAZIDE 165 157 12 10
PANTOPRAZOLE SODIUM 158 146 13 18
FUROSEMIDE 151 145 14 5
WARFARIN SODIUM 149 138 15 12
POTASSIUM CHLORIDE 139 129 16 26
ZOLPIDEM TARTRATE 118 112 17 19
RAMIPRIL 97 91 18 96
NAMENDA 94 94 19 38
TRAZODONE HCL 93 90 20 36
TRAMADOL HCL 92 80 21 16
ATENOLOL 91 82 22 14
DIOVAN 90 83 23 35
AZITHROMYCIN 89 79 24 42
GABAPENTIN 84 71 25 17
DONEPEZIL HCL 79 79 26 22
SERTRALINE HCL 78 70 27 23
METFORMIN HCL 77 63 28 9
VENLAFAXINE HCL ER 75 47 29 140
LEVOFLOXACIN 73 58 30 75
CLOPIDOGREL 73 52 30 32
BENICAR 71 70 32 153
CRESTOR 70 56 33 25
METFORMIN HCL ER 69 46 34 80
JANTOVEN 68 68 35 52
OXYCODONE-ACETAMINOPHEN 66 43 S2 36 44
SYNTHROID 66 66 36 72
ENALAPRIL MALEATE 64 57 38 79
RANITIDINE HCL 63 58 39 27
TAMSULOSIN HCL 60 56 40 31
PREDNISONE 55 48 41 45
POLYETHYLENE GLYCOL 3350 54 47 42 50
CEPHALEXIN 52 48 43 113
LOSARTAN POTASSIUM 52 47 43 15
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 20, 2008.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.